Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2026)

Pacific Biosciences Of California's Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $54000.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 99.64% year-over-year to $54000.0; the TTM figure through Mar 2026 stood at $54000.0 (down 99.96% YoY), while the FY2025 annual figure was $15.0 million, down 62.5% from the prior year.
• Asset Writedowns and Impairment was $54000.0 for Q1 2026 at Pacific Biosciences Of California, down from $15.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $93.2 million in Q2 2024 to a low of -$4.7 million in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $11.1 million across 5 years, with a median of $774000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment sank 99.91% in 2024, then soared 499900.0% in 2025.
• A 5-year view of Asset Writedowns and Impairment shows it stood at -$2.7 million in 2022, then sank by 75.89% to -$4.7 million in 2023, then surged by 873.5% to $36.3 million in 2024, then slumped by 58.66% to $15.0 million in 2025, then sank by 99.64% to $54000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $54000.0 (Q1 2026), $15.0 million (Q1 2025), and $36.3 million (Q4 2024), per Business Quant data.